Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
ViroMed’s myocardial infarction therapy cleared for phase 2 trial
By 황유미Published : Aug. 1, 2016 - 14:07
[DISCLOSURE] ViroMed (084990) announced on Aug. 1 that its VM202RY has been approved to initiate phase 2 of its clinical trials. VM202RY is a medicine for acute myocardial infarction by directly injecting into the cardiac muscles of the coronary artery territory.
